Rationale: Stem cell therapies to regenerate damaged cardiac tissue represent a novel approach to treat heart disease. However, the majority of adoptively transferred stem cells delivered to damaged myocardium do not survive long enough to impart protective benefits, resulting in modest functional improvements. Strategies to improve survival and proliferation of stem cells show promise for significantly enhancing cardiac function and regeneration.
S tem cell therapies are being explored as a novel way to treat heart failure. [1] [2] [3] [4] [5] Unfortunately, to date, relatively modest improvements in cardiac structure and function have been observed, in part, because of poor stem cell proliferation and viability after delivery. To improve benefits of stem cell therapy, mechanisms promoting proliferation and survival of the stem cell population without inhibiting lineage commitment have become an area of intense research focus. Enhanced efficacy of genetically modified stem cells mediating myocardial regeneration following infarction has been demonstrated using Pim-1, a cell survival and proliferation kinase downstream of Akt/PKB. 6 Akt/PKB is a pivotal regulatory kinase with various roles regarding growth, metabolism, and survival. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In the heart, Akt is among the most well-studied cardioprotective kinases with well-documented capacity to prevent cardiomyopathic injury. 6,19 -26 Activation of Akt is initiated by growth factor dependent stimulation of receptor tyrosine kinases, which in turn stimulate a cascade of signaling events beginning with the activation of PI3 kinase (PI3K) at the plasma membrane. Subsequent activation of PDK1/2 (phosphoinositidedependent kinase-1/2) phosphorylates and activates Akt. Downstream targets of Akt are numerous and include proproliferative and antiapoptotic substrates. 10, 14, 18, 20, [27] [28] [29] To investigate mechanisms governing cardioprotective effects of Akt, a variety of systems including cardiac-specific overexpression and viral infections have been used. Numerous studies attribute short-term Akt activation to the profound protective effects seen in postischemic injury models, whereby Akt induces secretion of paracrine factors, drastically increases cell cycle and inhibits apoptosis in cardiomyocytes. 14,19 -22,24 -26,30 Additionally, Akt activation stimulates neoangiogenesis and vasculogenesis, [31] [32] [33] in part accounting for the dramatic improvements seen in pathologically chal-lenged Akt transgenic mice. However, constitutive activation of Akt can have detrimental effects on the myocardium, including hypertrophic growth and abnormal vascular remodeling 34 ; the majority of protective effects afforded by Akt have been found to be governed through its nuclear localization. 14, 21, 24, 35 Previous studies by our group demonstrate cardiac specific overexpression of nuclear Akt allows for expansion of the progenitor cell pool, as well as enhanced protection of the myocardium against pathological injury without induction of hypertrophic remodeling. 14 Although the cardioprotective effects of nuclear Akt are clear within myocytes of transgenic animals, protective effects of nuclear Akt expression on the cardiac progenitor cell population have not been investigated. The present study evaluates the ability of cardiac progenitor cells (CPCs) modified with nuclear Akt (CPCeA) to mediate cardioprotection in infarcted hearts.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Lentiviral Vectors and Generation of Lentivirus
Bicistronic lentiviral vectors were generated as previously described. 6
CPC Isolation, Cell Culture, and Lentiviral Infection
CPCs isolated from 10 to 12-week-old male FVB mice, cultured in cardiac stem cell media and infected with lentivirus as previously described. 6 Cells were incubated with Akt kinase inhibitor-V (AIV) (10mol/L) for 7 days with and without dexamethasone (Dex) at 10
Ϫ8 mol/L where indicated.
Trypan Blue and CyQuant Assays
Uninfected, CPCe, and CPCeA cells were plated in quadruplicate (10 000 cells/well) in 24-well plates. To determine proliferation rate cells were harvested at 96-hours and stained 1:10 with trypan blue. Viable cells determined by trypan blue exclusion were counted. CPCe and CPCeA were plated in quadruplicate in 96-well plates (4000 cells/well), and CyQuant (Invitrogen) reagent was added at indicated time points, incubated for 45 minutes, and read at 530 nm.
Immunoblots, Immunohistochemistry, and Confocal Microscopy
Immunoblots, immunohistochemistry, and confocal microscopy were performed as previously described 6 with additional details in the Online Methods section.
C-kit ؉ Cell Quantification
Sections from CPCe-or CPCeA-injected animals were immunolabeled with antibodies against c-kit, GFP, and tropomyosin. Tropomyosin was used to measure infarct area using Leica confocal software. Total c-kit ϩ cells, c-kit ϩ GFP ϩ and c-kit ϩ GFP Ϫ CPCs were quantified in the infarct area.
Myocardial Infarction, Injections, Echocardiography, and Hemodynamics
Infarctions, echocardiography, and hemodynamics were performed as previously described, 6 with additional details provided in the Online Methods section. Animals were injected at 5 sites surrounding the border zone with PBS, CPCe, or CPCeA (total of 100 000 cells per heart). 
SuperArray and Quantitative Real-Time Polymerase Chain Reactions
For quantitative real-time polymerase chain reaction (qRT-PCR), RNA was harvested as per the protocol of the manufacturer (Zymo Research, R1055). cDNA was obtained using iScript cDNA synthesis kit (Bio-Rad, 170 to 8891). qRT-PCR was run using the iQ SYBR Green Supermix (Bio-Rad, 170 to 8882) because cDNA was synthesized. Cell proliferation array (SuperArray, PAMM-020) was performed according to the protocol of the manufacturer. Primers for qRT-PCR were designed using PubMed Primer-blast. Sequences provided in the Online Methods section.
Enzyme-Linked Immunosorbent Assay
Cells were plated at 3000 cells/well in 150 mL of stem cell media and cell culture supernatant harvested 24-hours later. SDF-1 ELISA was run according to the protocol of the manufacturer (RayBiotech, ELM-SDF1alpha-001).
Statistics
Statistics were calculated using Prism software. One-way ANOVA and 2-way repeated-measures ANOVA analysis for echocardiography with Tukey post hoc test were calculated. Values with PϽ0.05 were considered statistically significant.
Animal Studies
All animal studies were performed in accordance with IACUC approved protocols. 
Results

Overexpression of Nuclear-Akt in CPCs
CPCeA Increase Proliferation and Alter Expression of Cell Cycle Genes
The proliferation rate of CPCeA was significantly (PϽ0.01) increased relative to CPCe, over a 96-hour time course as determined by Trypan blue exclusion measuring total number of viable cells ( Figure 1A ). Additionally, CPCeA have a significant (PϽ0.05) increase in proliferation compared with CPCe over a 96-hour time course as determined by CyQuant assay ( Figure 1B ). Proliferation was attenuated in CPCeA and CPCe by 96-hours with addition of AIV ( Figure 1B ). Altered RNA expression for several cell cycle genes was confirmed in CPCeA compared with CPCe controls by cell cycle array (Online Figure II, A) . Specifically, cyclin-D1 protein is 
Increased Number of C-kit ؉ Cells in Hearts Receiving CPCeA
To assess whether protective benefits are gained from intramyocardial injection of CPCeA, 12-week-old female mice were subjected to infarction and CPCe or CPCeA were adoptively transferred. The number of c-kit ϩ cells was quantified within the infarct region of animals receiving PBS, CPCe or CPCeA. At 12 weeks, CPCeA-injected hearts had a significant (PϽ0.01) 2.3-fold increase in total c-kit ϩ cells compared with CPCe-injected controls (Figure 2A ). Additionally, CPCeA-injected hearts had a significant (Pϭ0.005) 2.7-fold increase in c-kit ϩ eGFP ϩ cells ( Figure 2B ) and a 1.8-fold increase in c-kit ϩ eGFP-cells (PϽ0.05) ( Figure 2C ) compared with CPCe-injected controls. There was no statistical difference (PϾ0.05) in the number of c-kit ϩ eGFP Ϫ cells between CPCe and saline-injected hearts. Although a significant number of c-kit ϩ GFP ϩ CPCs were identified in hearts receiving CPCeA after 12 weeks, there was a noticeable lack of GFP ϩ CPCs expressing markers consistent with cardiac lineage commitment as evidenced by the absence of colocalization between GFP and desmin or sarcomeric ␣-actin ( Figure 2D and 2E). In comparison, control CPCe acquire markers consistent with cardiogenic lineage commitment after infarction (Online Figure III and previously published data 6 ).
CPCeA Do Not Improve Function or Structure of Infarcted Myocardium
Cardiac function, after infarction and injection, was assessed by echocardiography and in vivo hemodynamics. Hearts of animals receiving CPCeA did not show a statistically significant improvement over CPCe-injected hearts in anterior wall dimension ( Figure 3A ), fractional shortening ( Figure 3B ), or ejection fraction ( Figure 3C ), at 12 weeks as assessed by 2-way ANOVA statistical analysis. Hemodynamic assessment further confirmed deterioration of cardiac function in CPCeA-injected animals as assessed by left ventricular developed pressure ( Figure 3D ), left ventricular end diastolic pressure ( Figure 3E ), and dP/dT maximum and minimum ( Figure 3F ). In fact, as early as four weeks postinjection, cardiac function in CPCeA-injected hearts was not statistically different (PϾ0.05) from PBS-injected controls. CPCeinjected hearts show a statistically significant (PϽ0.05) improvement in cardiac function at early time points (4 weeks), but beneficial effects were not sustained and were indistinguishable from PBS-injected controls by 12 weeks (Figure 3 ). Additionally, at 12 weeks after infarction, CPCeA-injected animals did not have a statistically significant reduction in infarct size compared with CPCe-injected controls (Online Figure IV) .
CPCeA Express Paracrine Factors Induced by Akt Activity
Increase numbers of endogenous (eGFP Ϫ , c-kit ϩ ) stem cells within the infarct ( Figure 2C) suggests CPCeA release paracrine factors promoting recruitment of resident CPCs to the site of injury. Thus, mRNA expression of paracrine factors known to be induced by Akt activity was assessed by quantitative RT-PCR (qRT-PCR) on CPCeA in vitro. CPCeA express significantly (PϽ0.001) more transcripts for FGF-2, FST-1, SDF-1 and VEGF ( Figure 4A ). CPCeA exhibit a significant 3.5-fold increase in SDF-1 protein expression compared with CPCe controls by ELISA assay ( Figure 4B ). Interestingly, SDF-1 is a potent chemoattractant, previously demonstrated to attract stem cells to sites of injury. 36, 37 CPCeA Abrogate In Vitro Differentiation
Absence of in vivo structural and functional improvement, combined with the observation that injected CPCeA did not appear to acquire markers consistent with cardiac lineage commitment, prompted assessment of CPCeA capacity for differentiation in vitro. CPCe and CPCeA were treated with dexamethasone (Dex) for seven days to induce differentiation and evaluated for c-kit protein expression by immunocytochemistry. CPCeA maintained c-kit expression after treatment with Dex in contrast to CPCe controls whereby c-kit expression was lost ( Figure 5, right) . Both CPCe and CPCeA expressed c-kit before Dex treatment ( Figure 5, left) . In addition to retention of c-kit expression on differentiation stimulation, CPCeA also fail to induce cardiac troponin (cTn)T, Mef2C, or Gata4 transcripts, markers consistent with cardiogenic lineage commitment ( Figure 6A through 6C) . In contrast, CPCeP express significantly (PϽ0.001) more Mef2C and Gata4 transcript than CPCeA when treated with Dex (Online Figure V) .
Elevated Levels of Phosphorylated CREB in CPCeA
cAMP response element binding protein (CREB) is a downstream target of Akt and has been previously demonstrated to promote progenitor cell proliferation. 12, 38 CPCe and CPCeA were treated with and without Dex for seven days and immunoblotted to assess CREB phosphorylation status. Undifferentiated CPCeA had a statistically significant (Pϭ0.007) 3.3-fold increase in the level of phospho-CREB compared with CPCe ( Figure 7A and 7B). The differential in CREB phosphorylation was even greater after differentiation, with Dex treated CPCeA showing a 19-fold significant (Pϭ0.0003) increase in the level of phospho-CREB compared with Dex treated CPCe controls ( Figure 7B ). By comparison, increases in phospho-CREB after differentiation were not observed in CPCeP (Online Figure VI) .
Attenuation of Akt Activity Increases Cardiac Lineage Commitment
CPCe and CPCeA were treated in vitro with inhibitor (AIV) to inhibit Akt kinase activity and subjected to Dex induced differentiation. CPCeA treated with AIV and Dex show a statistically significant (PϽ0.002) 2.7-fold reduction in phospho-CREB protein expression ( Figure 8A ) compared with Dex treated CPCeA without AIV treatment. Presumably nuclear Akt activity blocks the capacity of CPCeA to undergo lineage commitment on exposure to Dex. Therefore CPCeA and CPCe were treated with AIV and assessed for transcript levels of cTnT either with or without Dex exposure. CPCe and CPCeA do not express cTnT before Dex-induced differentiation ( Figure 8B) as detected by qRT-PCR. In contrast, on induction of differentiation CPCeA express low levels of cTnT, although at significantly (PϽ0.008) reduced levels compared with CPCe controls ( Figure 8B ). Next, treatment of CPCeA and CPCe with AIV before Dex-induced differentiation was performed to confirm overexpression of nuclear Akt in CPCeA abrogates cardiac lineage commitment. Indeed, CPCeA treated with AIV and Dex had a significant reduction in phospho-CREB protein levels ( Figure 8A ) as well as a statistically significant (PϽ0.008) increase in cTnT transcript ( Figure 8C ), compared with CPCeA treated with 
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Dex alone. CPCe also had significant increases in TnT transcript after treatment with AIV and Dex, compared with CPCe treated with Dex alone (Figure 8C ), although the difference was not as dramatic as in CPCeA.
Discussion
For years, treatment of the damaged myocardium has had the major limitation of being unable to regenerate functional cardiac tissue. Pharmaceutical treatments prolong the life of many patients, but ultimately fail as a permanent "fix" for treatment of heart failure. Recently, the advent of stem cell research and tissue regeneration presents a potential longterm solution for the repair of damaged myocardium. Clinical trials whereby stem cells are delivered to the damaged myocardium are underway; however, results generally offer modest short-term improvements in cardiac function. A plausible biological explanation for the underwhelming outcomes of such adoptive transfer studies is that only a minority of delivered stem cells survives in damaged myocardium. These observations led to the hypothesis that increasing the ability of adoptively transferred stem cells to survive and proliferate will significantly improve efficacy of stem cell regeneration in the heart. Genetic modification of stem cells with survival kinases, in particular Akt and associated downstream targets, improves the ability of progenitor cells to mitigate cardiac damage and improve regeneration. 6, 26, 39 Although constitutive activation of Akt leads to hypertrophic growth and abnormal vascular remodeling, a plethora of studies have shown short-term Akt activation, as well as nuclear localized Akt, imparts protective benefits including growth, inhibition of cell death and increased angiogenesis to the pathologically challenged heart. However, successful modification of stem cells requires the ability to increase proliferation and survival without inhibiting lineage commitment following appropriate environmental stimulation. The majority of experiments involving Akt overexpression in stem cells do not measure the amount or the duration of this stimulation within the progenitor cell pool. 19, 22, 26, 40 Although protective benefits have been gained through Akt activation, several studies also demonstrate sustained overexpression can inhibit lineage commitment and terminal differentiation in various progenitor cell populations. 12, 41 Overexpression of nuclear Akt dramatically increases CPC proliferation and significantly expands the cell population in vitro (Figure 1 ), likely resulting from regulation of various cell cycle genes (Online Figure II) . Although we previously reported activation of Pim-1 downstream of nuclear Akt in myocytes, 20 Pim-1 expression in CPCs was not increased in CPCeA when compared with controls (Online Figure I, C) . The basis for this differential action of nuclear Akt accumulation on Pim-1 expression is unknown at present, but presumably is tied to context-dependent cross-talk between nuclear Akt and Pim-1 depending on the cell type and possibly proliferation status.
CPCeA-injected hearts also retain significantly more c-kit ϩ GFP ϩ cells after infarction compared with CPCe controls, indicating CPCeA had increased proliferation in vivo (Figure 2A, 2B, and 2E ). Numerous studies also demonstrate modification of progenitor cells with Akt, induces secretion of paracrine factors, 23, 30, [42] [43] [44] promoting survival of endogenous myocardium as well as the adoptively transferred population. Similarly, CPCeA secrete paracrine factors, most notably SDF-1 ( Figure 4A and 4B) , a chemoattractant that promotes recruitment of stem cells to sites of injury. SDF-1 production by CPCeA may account in part for the observed increase of endogenous c-kit ϩ GFP-cells to the infarct. Although the majority of the c-kit ϩ GFP Ϫ population are presumably endogenous CPCs at the time of assessment, we cannot exclude the possibility that SDF-1 secretion also leads to increased homing of bone marrow stem cells to the infarct in CPCeA-injected hearts ( Figure 2C ) that may include mast cells. Regardless of cell origin, the increase in endogenous c-kit ϩ cells observed in CPCeA-injected animals, whether CPCs, bone marrow cells, mast cells, or a combination, does not mediate salutary action in the infarcted myocardium ( Figure 3) .
Although CPCeA persistence after adoptive transfer into infarcted hearts was significantly improved compared with CPCe controls there was no concurrent benefit for myocardial function (Figure 3 Figure V) . These effects are likely the consequence of Akt-mediated deregulation of cell cycle control and overriding normal differentiation programming. These results help to explain, at least in part, the stark contrast in protective benefits afforded by CPCeP 6 but not from CPCeA when delivered to the infarcted heart. 
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The transcription factor CREB is phosphorylated and activated by Akt on serine 133. 12, 45 Phosphorylation of CREB induces proliferation and elevated levels of phosphorylated CREB are found in several forms of cancer. 46 Chondrocyte progenitor cells overexpressing Akt and phospho-CREB were highly proliferative but also refractory to differentiation, 12 consistent with our observations of CPCeA. Furthermore, terminal differentiation of chondrocyte progenitor cells was observed only after inhibition of Akt activity. 12 Similarly in our studies, inhibition of Akt activity in CPCeA reduced phospho-CREB levels 2.7-fold ( Figure 8A) and resulted in increased expression of cardiac TnT transcript, a marker consistent with cardiogenic differentiation (Figure 8B and  8C) . In contrast to CPCeA, CPCeP do not overexpress phospho-CREB after differentiation (Online Figure VI) and are capable of cardiogenic lineage commitment (Online Figure V ). 6 Collectively, our findings are consistent with previous studies demonstrating high levels of Akt expression promote rapid proliferation of progenitor cells that must be attenuated to initiate lineage commitment. 41 Thus, it seems evident that despite long-term persistence and enhanced proliferation, the successful differentiation of adoptively transferred stem cell populations is essential for amelioration of damage after pathological injury. Although transient overexpression of cardioprotective genes would provide short-term rapid expansion of the progenitor cell pool and increased survival within the damaged myocardium, sustained protective benefits necessary for clinical implementation would likely be lost. Our results suggest fostering stable cell proliferation and survival may come at the expense of efficient differentiation. Possible solutions to achieve the best possible outcome could use regulated gene expression to control progenitor cell biology after adoptive transfer, allowing for temporal reactivation of the cardioprotective gene as well as increased control over the activation of proproliferative and prosurvival genes. Alternatively, an episomal vector strategy such as adeno-associated virus or minicircle delivery systems that allow temporally limited but persistent expression could provide sufficient beneficial signaling during the critical time window of days to weeks after adoptive transfer. Episomal genetic modifications obviate concerns related to oncogenic transformation resulting from random integration into the genome as well as eventual diminution of expression over time and ongoing cellular proliferation. Studies are presently being pursued to examine the potential utility of inducible or episomal delivery systems to augment survival and proliferative signaling in CPCs.
Short-term studies consistently demonstrate delivery of paracrine factors facilitate minor improvements in structure and function of the damaged myocardium. 22, [42] [43] [44] [47] [48] [49] [50] However, despite secretion of paracrine factors from CPCeA that likely contribute to early minor improvements in myocardial function ( Figure 3A through 3C) long-term benefits from paracrine signaling were not evident. Recently, our group published a study demonstrating CPCs modified with Pim-1, a downstream target of Akt, were able to promote regeneration and impart drastic improvements to damaged myocardium. Significantly, the major difference between the two studies was that CPCeP were able to transdifferentiate (On-line Figure V ). 6 Although CPCeA delivery enhances endogenous CPC recruitment that presumably are capable of lineage commitment, 6 the increase in endogenous CPCs fails to provide functional improvements in the damaged myocardium. Thus, improving endogenous repair responses may modestly increase short-term benefits to infarcted myocardium but ultimately fail to bring about the magnitude of a response necessary for meaningful regeneration. Collectively, results presented here help to reconcile the argument that although paracrine factor delivery may provide minor benefits, it is not sufficient for long-term improvements in structure and function of the damaged myocardium.
Genetic modification of stem cell populations with cardioprotective genes has now been demonstrated in numerous studies as a legitimate approach to foster repair and regeneration in the pathologically damaged heart. Importantly, this study demonstrates that although paracrine factors may mitigate damage in early stages, CPC commitment is essential to the long-term regenerative response. Therefore, effective cardiac stem cell therapies must promote cellular survival and proliferation, as well as long-term engraftment and successful lineage commitment of the donated cell population.
